UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Cost allocation in antihypertensive drug therapies

Esposti, LD; Baio, GL; Valpiani, G; Buda, S; Sturani, A; Esposti, ED; (2002) Cost allocation in antihypertensive drug therapies. Expert Review of Pharmacoeconomics and Outcomes Research , 2 (5) 419 - 426. 10.1586/14737167.2.5.419.

Full text not available from this repository.

Abstract

The objective of this paper is to evaluate persistence with treatment and resources allocation in antihypertensive pharmacotherapy in a 'real world' population. An administrative database listing all purchased drugs was used to perform a longitudinal analysis. The study included all new users over 20 years of age receiving a first prescription for amlodipine, atenolol, fosinopril, indapamide, or losartan, in an enrolment period of 12 months. The follow-up period lasted 12 months. According to prescriptions dynamics, subjects were classified as same therapy, combination, switching, interruption and occasional utilization. The 34.9% study cohort, persisted with treatment (21.1% on same therapy, 4.7% on combination and 9.1% on switching), while 65.1% did not persist (10.9% on interruption and 54.2% on occasional use). The overall drug cost accounted for persistent (69.0%) and nonpersistent subjects (31.0%). The annual average cost ranged from ε32.80 for occasional users to ε274.69 for those in combination. In clinical practice, a high percentage of patients do not receive adequate antihypertensive therapy, since the 65.1% of subjects did not persist with treatment. This results in a level of pharmaceutical expenditure that cannot be considered appropriately allocated.

Type:Article
Title:Cost allocation in antihypertensive drug therapies
DOI:10.1586/14737167.2.5.419
UCL classification:UCL > School of BEAMS > Faculty of Maths and Physical Sciences > Statistical Science

Archive Staff Only: edit this record